Clinical Trials

Phase EARLY_PHASE1 Completed

Pancreatic Neoplasms

NCT05555342 2025-05-14

A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm

6 enrolled

Lung Neoplasms, Neoplasm Metastasis

NCT04972097 2025-02-12

PRESERVE

121 enrolled

Prostatic Neoplasms

NCT03630640 2024-07-31

NIVOLEP

Phase 2 Completed

43 enrolled

Carcinoma, Hepatocellular

NCT03185013 2023-07-27

REVEAL 1

Phase 3 Completed

201 enrolled 23 charts

Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT02531425 2023-05-15

TNBC

Phase 1 Completed

10 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01939665 2022-12-20

PANFIRE

50 enrolled

Pancreatic Neoplasms

NCT02082782 2022-12-20

COLDFIRE-2

Phase 2 Completed

51 enrolled

Colorectal Liver Metastases

NCT02791503 2022-12-20

CROSSFIRE

74 enrolled

Pancreatic Neoplasms

NCT03257150 2022-08-11

A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer

12 enrolled

Pancreatic Ductal Adenocarcinoma

NCT02329106 2021-09-05

Percutaneous Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome

Liver Neoplasms

NCT02333773 2021-09-05

IRE

15 enrolled

Liver Neoplasms

NCT02335112 2021-09-05

IRE

15 enrolled

Head & Neck

Head and Neck Neoplasms

NCT02335827 2021-09-05

IRE

15 enrolled

Carcinoma, Renal Cell

NCT02425059 2021-09-05

Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms

Rectal Neoplasms

NCT02430597 2021-09-05

IRE

Hilus Pulmonary Neoplasms

NCT02430610 2021-09-05

IRE

Gynecologic

Uterine Cervical Neoplasms

NCT02430623 2021-09-05

IRE

Urinary Bladder Neoplasms

NCT02430636 2021-09-05

IRE

Stomach Neoplasms

NCT02430662 2021-09-05

IRE

Gallbladder Neoplasms

NCT02430675 2021-09-05

IRE

Head & Neck

Laryngeal Neoplasms

NCT02430688 2021-09-05

IRE

Extremities Neoplasms

NCT02430701 2021-09-05

IRE

Esophageal Neoplasms

NCT02430753 2021-09-05

IRE

Lung Neoplasms

NCT02430766 2021-09-05

IRE

Lymphatic Metastasis

NCT02430779 2021-09-05

IRE

Ureteral Neoplasms

NCT02981719 2021-01-22

Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer

61 enrolled

Pancreatic Neoplasms

NCT03180437 2020-11-02

Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer

62 enrolled

Pancreatic Neoplasms

NCT03183219 2020-07-13

Safety and Efficiency of γδ T Cell Against Liver Cancer

Liver Neoplasms

NCT03183232 2020-07-13

Safety and Efficiency of γδ T Cell Against Lung Cancer

Lung Neoplasms

NCT02828865 2020-07-07

A Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers

18 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02841436 2020-07-07

A Clinical Research About Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer

7 enrolled

Pancreatic Neoplasms

NCT02718859 2019-09-12

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

60 enrolled

Pancreatic Neoplasms

NCT03008343 2019-09-12

Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer

20 enrolled

Carcinoma, Hepatocellular

NCT03239158 2019-01-25

Bioinformation Therapy for Liver Cancer

Liver, Cancer of, Non-Resectable

NCT03239171 2019-01-25

Bioinformation Therapy for Lung Cancer

Small Cell Lung Carcinoma

NCT03239184 2019-01-25

Bioinformation Therapy for Pancreatic Cancer

Unresectable Pancreatic Cancer

NCT03240224 2019-01-25

Bioinformation Therapy for Breast Cancer

Breast

Advanced Breast Cancer

NCT03350477 2019-01-25

Bioinformation Therapy for Gastric Cancer

Advanced Gastric Cancer

NCT03350490 2019-01-25

Bioinformation Therapy for Intestinal Cancer

Advanced Intestinal Cancer

NCT01790451 2015-02-20

Safety and Efficacy of Irreversible Electroporation in Ablation of Prostate Cancer in Humans

Phase 1 Completed

16 enrolled

Prostatic Neoplasms

NCT02010801 2013-12-13

Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors

20 enrolled